Media Center
Publicaciones
Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models
Published online: 02 Nov 2022
https://doi.org/10.3389/fonc.2022.943064
ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models
Posted online: 1 June 2022
https://doi.org/10.1002/cac2.12282
Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC
IASLC, 2020 World Conference on Lung Cancer, Singapore, January 2021
Phase 2 of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin as first-line treatment in advanced/recurrent endometrial cancer
ESMO 2020 - Abstract 2727
C. Domènech , J. Alfon, I. Ray-Coquard, A. Oaknin
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.
Posted online: 13 May 2020
https://doi.org/10.1080/15548627.2020.1761651
Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma
Meeting: 2019 ASCO Annual Meeting - Abstract No: 3089 - Poster Board Number: Poster Session (Board 81) - Citation: J Clin Oncol 37, 2019 (suppl; abstr 3089)
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
Published: Gynecol Oncol. 2019 Mar 7
S0090-8258(19)30150-7
ABTL0812, a novel phase-2 clinical stage pro-autophagic anti-cancer compound with potential clinical activity in cholangiocarcinoma
2019 Cholangiocarcinoma Foundation Annual Conference
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
1st Oncobell Symposium. Mechanisms of Cancer and New Therapeutic Strategies. Barcelona 2018.
Exploring pharmacokinetic/pharmacodynamic considerations in translational oncology; from preclinical development to Phase II operations
Outsourcing in Clinical Trials. Barcelona 2018.
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
16th International Congress ASEICA, 2018.
Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812
J Clin Oncol 36, 2018 (suppl; abstr e14556).
The new antitumoral drug ABTL0812 induces autophagic cell death by a dual mechanism: inhibition of Akt/mTORC1 axis and impairing desaturase-1 activity.
Transautophagy, Copenhaguen 2017.
Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling
Published: 11 Oct. 2016
Ann Oncol (2016) 27 (suppl_6): 378P
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Published: 15 May 2016
10.1158/1078-0432.CCR-15-1808
ÚLTIMAS NOTICIAS
Notas de Prensa
Ability Pharmaceuticals anuncia la presentación de los resultados de la fase 2a de ABTL0812 como terapia de primera línea en pacientes con cáncer de pulmón en el congreso anual ASCO 2023 en Chicago + infoNotas de Prensa
AbilityPharma logra el 30% del reclutamiento estimado para su ensayo clínico de fase 2b con ABTL0812 + FOLFIRINOX como tratamiento de primera línea en cáncer de páncreas avanzado + infoNotas de Prensa
AbilityPharma obtiene 1,5 millones de euros de financiación no dilutiva de los fondos de próxima generación de la UE para seguir estudiando los efectos inmunomoduladores anticancerígenos de ABTL0812 + infoNotas de Prensa
AbilityPharma participará en el LSX Investival Showcase en Londres para reunirse con potenciales inversores y firmas de capital riesgo + infoNotas de Prensa
ABTL0812 muestra potencial contra los tumores cerebrales de glioblastoma + infoNotas de Prensa
AbilityPharma obtiene 2,2 millones de euros de financiación no dilutiva del Ministerio de Ciencia e Innovación del Gobierno de España para acelerar el desarrollo clínico y la ruta regulatoria de ABTL0812 + infoNotas de Prensa
Carles Domènech, presidente ejecutivo y CEO de AbilityPharma, asistirá al Congreso ESMO en París para una reunión con algunos de los líderes de opinión clave (KOL) más relevantes en el tratamiento del cáncer de páncreas + infoNotas de Prensa
AbilityPharma asistirá al congreso mundial ESMO sobre cáncer gastrointestinal 2022 en Barcelona + infoNotas de Prensa
AbilityPharma asistirá al congreso ESMO en Cáncer Ginecológicos 2022 en Valencia + info